|37.39||-1.22||-3.16%||Vol 82.33K||1Y Perf 63.00%|
|Jan 21st, 2022 16:00 DELAYED|
|- -||-1.39 -3.72%|
|Target Price||42.00||Analyst Rating||Strong Buy 1.00|
|Potential %||12.33||Finscreener Ranking||★★★+ 51.04|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★ 52.11|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★+ 64.51|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||53.85||Earnings Rating||Strong Buy|
|Market Cap||461.47M||Earnings Date||4th Feb 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||4th Feb 2022|
|Estimated EPS Next Report||0.18|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||71.35K|
|Avg. Monthly Volume||65.80K|
|Avg. Quarterly Volume||68.74K|
iRadimed Corporation (NASDAQ: IRMD) stock closed at 37.39 per share at the end of the most recent trading day (a -3.16% change compared to the prior day closing price) with a volume of 82.63K shares and market capitalization of 461.47M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 114 people. iRadimed Corporation CEO is Roger Susi.
The one-year performance of iRadimed Corporation stock is 63%, while year-to-date (YTD) performance is -19.09%. IRMD stock has a five-year performance of 306.41%. Its 52-week range is between 21.65 and 50.88, which gives IRMD stock a 52-week price range ratio of 53.85%
iRadimed Corporation currently has a PE ratio of 91.80, a price-to-book (PB) ratio of 8.01, a price-to-sale (PS) ratio of 18.15, a price to cashflow ratio of 53.20, a PEG ratio of 2.32, a ROA of 8.21%, a ROC of 9.06% and a ROE of 9.50%. The company’s profit margin is 18.14%, its EBITDA margin is 22.70%, and its revenue ttm is $29.94 Million , which makes it $2.43 revenue per share.
Of the last four earnings reports from iRadimed Corporation, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.18 for the next earnings report. iRadimed Corporation’s next earnings report date is 04th Feb 2022.
The consensus rating of Wall Street analysts for iRadimed Corporation is Strong Buy (1), with a target price of $42, which is +12.33% compared to the current price. The earnings rating for iRadimed Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
iRadimed Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
iRadimed Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 11.88, ATR14 : 2.28, CCI20 : -206.82, Chaikin Money Flow : -0.25, MACD : -1.28, Money Flow Index : 23.10, ROC : -24.50, RSI : 30.00, STOCH (14,3) : 2.53, STOCH RSI : 0.00, UO : 28.92, Williams %R : -97.47), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of iRadimed Corporation in the last 12-months were: Anthony F. Vuoto (Option Excercise at a value of $0), Anthony F. Vuoto (Sold 3 690 shares of value $137 381 ), Chris Scott (Option Excercise at a value of $0), Chris Scott (Sold 70 000 shares of value $2 852 623 ), James B. Hawkins (Option Excercise at a value of $0), James B. Hawkins (Sold 148 059 shares of value $6 114 656 ), Monty Allen (Option Excercise at a value of $35 500), Monty Allen (Sold 4 597 shares of value $156 666 ), Roger Susi (Sold 210 000 shares of value $7 960 297 )
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.